STOCKHOLM, April 23, 2025 /PRNewswire/ -- Sobi^® (STO: SOBI) presents clinical data aimed at updating the global haemophilia community attending this year's WFH 2025 Comprehensive Care Summit in Dubai from the 23 - 25 April. New and updated outcomes and analyses will be presented from the XTEND phase 3clinical program testing the effectiveness of Altuvoct® (efanesoctocog alfa) treatment for haemophilia A, including updates on patients' joint health and surgical outcomes in patients.

"At WFH 2025 CCS, Sobi will present highlights from the XTEND phase 3 program and discuss the new treatment paradigm with FVIII levels in the non-haemophilia range. Sharing these clinical outcomes with the wider haemophilia community will help to ensure the latest treatment approaches are widely known and understood," said Lydia Abad-Franch, MD, MBA, Head of Research, Development, and Medical Affairs (RDMA), and Chief Medical Officer at Sobi.

Key data to be presented at WFH 2025 Comprehensive Care Summit, Dubai, UAE
Altuvoct® (efanesoctocog alfa)




     
     Oral Presentations


              .             A plain language summary of the association    
            Oral presentation: Oral FP-TH-02.5
                   between joint health and patient reported
                   quality of life outcomes using data from the            
            Date: Thursday 24 April 2025
                   efanesoctocog alfa Phase 3 clinical trial in
                   adults and adolescents with severe                      
            Time: 08:45 - 09:00
                    haemophilia A
                                                       .
                                                                                  Location: Great Ballroom
                                                                                                              .


                            Efanesoctocog alfa for the perioperative       
            Oral presentation: Oral FP-WE-01.5
                   management of dental surgery in                         Date: Wednesday 23 April
                   participants with severe hemophilia A: 4
                   years of experience during the XTEND clinical
                   program
                                                                         
            Time: 16:15 - 16:30



                                                                         
            Location: Great Ballroom





     
     Posters


                            SHINE study design: An interventional, open-   
            Poster presentation: Poster PO-179
                   label, Phase 4 study investigating changes in
                   synovial hypertrophy in patients with                   
            Presentation dates and times:
                   haemophilia A on efanesoctocog alfa                     Wednesday 23 April / 11:00 - 11:30
                   prophylaxis
                                                                         
            Thursday 24 April / 11:00 - 11:30

                                                                                  Poster Networking Event: Thursday 24
                                                                         April / 19:00 - 20:00


                   
            Long-term outcomes of prophylaxis with         
            Poster presentation. Poster PP-044
                   efanesoctocog alfa in adults and adolescents
                   previously treated on demand: second                    
            Presentation dates and times:
                   interim analysis of XTEND-ed                            Wednesday 23 April / 11:00 - 11:30

                                                                         
            Thursday 24 April / 11:00 - 11:30

                                                                                  Poster Networking Event: Thursday 24
                                                                         April / 19:00 - 20:00


                            Plain language summary of two-year results     
            Poster presentation. Poster PP-045
                   of weekly efanesoctocog alfa treatment in
                   children with severe haemophilia A: Interim             
            Presentation dates and times:
                   analysis of the XTEND-ed phase 3 study                  Wednesday 23 April / 11:00 - 11:30

                                                                         
            Thursday 24 April / 11:00 - 11:30
                                                                         Poster Networking Event: Thursday 24
                                                                         April / 19:00 - 20:00


                            Plain language summary: Efanesoctocog alfa     
            Poster presentation. Poster PP-046
                   treatment outcomes over 3 years in adults
                   &amp; adolescents with severe haemophilia               
            Presentation dates and times:
                   A in the long-term XTEND-ed study                       Wednesday 23 April / 11:00 - 11:30

                                                                         
            Thursday 24 April / 11:00 - 11:30

                                                                                  Poster Networking Event: Thursday 24
                                                                         April / 19:00 - 20:00


                   
            The A-MOVE study easily explained: the         
            Poster presentation: Poster PP-043
                   value of regular joint assessments in
                   individuals with haemophilia                            
            Presentation dates and times:
                                                                         Wednesday 23 April / 11:00 - 11:30

                                                                         
            Thursday 24 April / 11:00 - 11:30

                                                                                  Poster Networking Event: Thursday 24
                                                                         April / 19:00 - 20:00

About efanesoctocog alfa

Efanesoctocog alfa [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein] (formerly BIVV001) is a novel and significant part of the week factor VIII therapy. It has the potential to deliver near-normal factor activity levels for significant parts of the week, improving bleed protection in a once-weekly dose for people with haemophilia A. Efanesoctocog alfa builds on the innovative Fc fusion technology by adding a region of von Willebrand factor and XTEN^® polypeptides to extend its time in circulation. It is the only therapy that has been shown to break through the von Willebrand factor ceiling, which imposes a half-life limitation on current factor VIII therapies. It was approved as ALTUVIIIO™ [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl] by Sanofi in the US in February 2023.

About the Sobi and Sanofi collaboration

Sobi and Sanofi collaborate on the development and commercialisation of Alprolix^® and Elocta^®/Eloctate^®. The companies also collaborate on the development and commercialisation of efanesoctocog alfa, referred to as ALTUVIIIO™ in the USA and ALTOVUCT in Europe. An investigational factor VIII therapy with the potential to provide high sustained factor activity levels with once-weekly dosing for people with haemophilia A. Sobi has final development and commercialisation rights in the Sobi territory (essentially Europe, North Africa, Russia and most Middle Eastern markets). Sanofi has final development and commercialisation rights in North America and all other regions in the world excluding the Sobi territory.

Sobi^®

Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Providing sustainable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,800 employees across Europe, North America, the Middle East and Asia. In 2022, revenue amounted to SEK 18.8 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com, LinkedIn and YouTube.

Contact
For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/swedish-orphan-biovitrum-ab/r/sobi-presents-clinical-data-at-wfh-2025-comprehensive-care-summit,c4138560

The following files are available for download:


     
     https://mb.cision.com/Main/14266/4138560/3400801.pdf Sobi presents clinical data at WFH 2025 Comprehensive
                                                              Care Summit

View original content:https://www.prnewswire.co.uk/news-releases/sobi-presents-clinical-data-at-wfh-2025-comprehensive-care-summit-302435383.html

Tags

More Like This

Sobi to present new data at EAHAD 2024

Sobi to present new data at ASH 2023 Annual Meeting

Sobi's strength in haematology to be showcased at ASH 2024

Sobi® receives positive CHMP opinion recommending approval of efanesoctocog alfa for once-weekly treatment of haemophilia A

Reminder: Sobi KOL investor event: Advancing the standard of care in haemophilia

European Commission grants Sobi® Marketing Authorisation for ALTUVOCT™ for treatment of haemophilia A

Sobi to share new clinical data and research at EULAR 2025

NEJM publishes ALTUVOCT® phase 3 XTEND-Kids results highlighting treatment potential for children with severe haemophilia A